Samsung Life Insurance Special Account Sells 3,001 Shares of Samsung Biologics via Open Market; Stake Edges Down to 74.30%, Minimal Impact on Shareholder Value

Samsung Life Insurance (Special Account) sold 3,001 common shares (0.01%) of Samsung Biologics via open market trades from May 4 to May 29, 2026, reducing its stake to 11,205 shares (0.02%)
Total stake of the largest shareholder and related parties decreased slightly by 0.01%p to 34,393,949 shares (74.30%), while major holders Samsung C&T (43.06%) and Samsung Electronics (31.22%) remain unchanged
The sale appears to be a minor portfolio adjustment by Samsung Life Insurance Special Account, representing only 0.01% of total outstanding shares, thus having limited impact on stock price or enterprise value
[AI Summary]The minimal stake sale (3,001 shares, 0.01%) by Samsung Life Insurance Special Account caused a negligible decline in the largest shareholder group's ownership from 74.31% to 74.30%, but this is routine portfolio rebalancing with no change in the core control structure by Samsung C&T and Samsung Electronics, resulting in no material impact on shareholder value